Added to YB: 2026-09-14
Pitch date: 2026-09-10
ORIC [neutral]
ORIC Pharmaceuticals, Inc.
Author Info
No bio for this author
Company Info
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States.
Market Cap
$1.3B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.83
P/E
-9.25
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Day 2 Section 3 - $ORIC
ORIC (quick overview): ORIC Pharmaceuticals is a two-shot oncology story led by rinzimetostat, now in the Himalayas-1 Phase 3 prostate-cancer study with topline data expected in 1H28. Its potential edge is cleaner PK and tolerability versus Pfizer’s competing PRC2 inhibitor; enozertinib must show best-in-class CNS activity and safety in EGFR-mutant NSCLC. Pfizer’s upcoming data and ORIC’s late-2026 lung-cancer readouts are key catalysts.
Read full article (1 min)